Ivan Hyep - 22 Jan 2026 Form 4 Insider Report for Bicara Therapeutics Inc. (BCAX)

Role
Chief Financial Officer
Signature
/s/ Lara Meisner, Attorney-in-Fact
Issuer symbol
BCAX
Transactions as of
22 Jan 2026
Net transactions value
-$27,030
Form type
4
Filing time
26 Jan 2026, 16:33:41 UTC
Previous filing
23 Dec 2025
Next filing
04 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Hyep Ivan Chief Financial Officer BICARA THERAPEUTICS INC., 116 HUNTINGTON AVENUE, SUITE 703, BOSTON /s/ Lara Meisner, Attorney-in-Fact 26 Jan 2026 0002034668

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BCAX Common Stock Options Exercise $7,132 +1,882 +1.3% $3.79 147,237 22 Jan 2026 Direct F1
transaction BCAX Common Stock Sale $34,162 -1,882 -1.3% $18.15 145,355 22 Jan 2026 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BCAX Stock Option (Right to Buy) Options Exercise $0 -1,882 -2.8% $0.000000 65,462 22 Jan 2026 Common Stock 1,882 $3.79 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 13, 2025.
F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.15 to $18.18, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
F3 The shares underlying this option vest in sixteen equal quarterly installments following April 5, 2023, subject to the Reporting Person's continued service on each such vesting date.